Gilnature/iStock by way of Getty Images
- Pharmaceutical firm ARCA biopharma (NASDAQ:ABIO) stated on Friday its board has accredited a reverse stock split of its shares at a ratio of 1-for-12.
- ARCA’s (ABIO) stock is anticipated to start buying and selling on a post-reverse stock split foundation on the Nasdaq Global Market on September 3, 2024.
- The firm’s stock will commerce beneath the brand new title Oruka Therapeutics, and beneath the brand new image “ORKA” after the closing of its merger with Oruka.
- The reverse stock split is anticipated to scale back ARCA (ABIO)’s frequent shares from about 14.5M shares to about 1.2M shares.
- ARCA’s shares had been down 3.85% throughout after-hours buying and selling.
Source: Seekingalpha